Early stage cervical cancer can be successfully treated with either surgery or radiotherapy, but medical therapy is inevitably necessary for the treatment of locally advanced and metastatic cases. Chemotherapy is routinely used to increase the efficacy of radiation therapy (chemoradiation) and in the palliative setting, but it has also been investigated as neoadjuvant and adjuvant therapy. Due to the limited efficacy of chemotherapies in cervical cancer and to the development of the oncological therapies, in the last decade many studies have been performed with novel agents. First the anti-VEGF antibody bevacizumab, later immunotherapeutic agents, lately an antibody drug conjugate have proven their efficiency and gained approval from the federal and European medical agencies. The aim of this paper is to give an overview of the medical therapies of cervical cancer (excluding chemoradiation), focusing on currently available modern treatment options and future possibilities.